Arcus Biosciences (RCUS) President Juan Jaen Sells $250K of Stock
Juan Jaen sold 9,236 shares of Arcus Biosciences, valued at $249,649.08.
Reviewed by automated data checks against the source filing. How we make and check alerts
Juan Jaen, President at Arcus Biosciences, Inc. ($RCUS), sold 9,236 shares at an average price of $27.03, worth about $249,649.08, on June 22, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $RCUS is up 14.1% after 1 week, up 10.1% after 1 month and down 18.8% to date (from the $27.23 close on Jun 22, 2026).
RCUS
Arcus Biosciences, Inc.
Key Points
- Juan Jaen, President of Arcus Biosciences, sold 9,236 shares for $249,649.08 on June 22, 2026.
- Shares of Arcus Biosciences traded near $29.05 with a market cap of $3.42 billion and a forward P/E ratio of -8.78.
- Analysts have set price targets for Arcus ranging from $22 to $49, with a consensus rating of 'strong buy'.
Get $RCUS trade alerts by text
We text you when insiders, Congress or big funds trade $RCUS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Arcus Biosciences, Inc. alert may contain errors. Disclosures
Juan Jaen, the President of Arcus Biosciences, Inc. (NYSE: RCUS), recently sold 9,236 shares of the company. The transaction, valued at $249,649.08, took place on June 22, 2026, at an average price of $27.03 per share. This sale was part of a pre-planned trading arrangement.
Insider Buying and Selling at Arcus Biosciences, Inc.
Juan Jaen has been active in the market recently, with multiple sales including 6,431 shares at $29.66 on June 24, and 15,764 shares at $27.73 on June 23, all as part of planned transactions. Additionally, Yasunori Kaneko purchased 16,900 shares on June 11, while Carolyn Tang, the General Counsel, sold and bought 34,090 shares on the same day.
Arcus Biosciences, Inc. Stock Up 15.1%
Shares of NYSE:RCUS traded near $29.05 on Thursday. Arcus Biosciences has a market cap of approximately $3.42 billion and a forward P/E ratio of -8.78, indicating it is not currently profitable. The stock's 52-week range spans from $7.91 to $28.72. It has a 50-day moving average of $24.26 and a 200-day moving average of $20.95. The company maintains a healthy current ratio of 4.04 and a quick ratio of 3.97, with a debt-to-equity ratio of 21.56.
Analysts Set New Price Targets
Analysts have been active in re-evaluating Arcus Biosciences. On June 4, 2026, LifeSci Capital initiated coverage with a 'buy' rating and a $46 price target. Truist Securities assumed coverage with a 'buy' rating and a $35 target on May 18. Morgan Stanley maintained a 'hold' rating with a $22 target on May 11. The consensus among 12 analysts is a 'strong buy' with a mean target price of $35.75.
About Arcus Biosciences
Arcus Biosciences, Inc., headquartered in Hayward, California, is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapies. The company has a diverse portfolio of products in various stages of clinical trials, including treatments for kidney, lung, and gastrointestinal cancers. Partnerships with major companies like AstraZeneca and Bristol-Myers Squibb support its research and development efforts. Led by CEO Dr. Terry J. Rosen, the company employs 601 people.
Bottom Line
Arcus Biosciences continues to be a focus for investors, with insider sales and analyst ratings highlighting its market activities. Juan Jaen's recent share sales were planned, suggesting strategic financial management. Investors should note that 13F filings and insider transactions are historical and may not reflect current positions.
Related Filing Alerts
Source: Juan Jaen's Form 4 filing on $RCUS (Jun 22, 2026). Find the original filing: RCUS Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts